期刊文献+

地榆升白片治疗妇科肿瘤化疗中白细胞减少症120例效果观察 被引量:12

下载PDF
导出
摘要 目的探讨地榆升白片治疗妇科肿瘤化疗中白细胞减少症的效果及安全性。方法将220例妇科肿瘤化疗过程中出现白细胞减少症患者随机分为观察组120例及对照组100例,观察组口服地榆升白片;对照组口服利血生片。30 d为一疗程,共2个疗程。治疗前及治疗后1周查血常规,观察白细胞变化。比较两组症状改善情况及不良反应发生情况。治疗30、60 d时判定疗效。结果观察组服药1周症状即开始好转,2~3周后症状明显改善。而对照组服药4周后部分症状方能缓解。两组均未发现明显不良反应。观察组治疗30、60 d时总有效率分别为87.50%、90.83%,对照组分别为65.00%、76.00%,P均<0.05。结论地榆升白片治疗妇科肿瘤化疗中白细胞减少症效果确切,且较为安全。
出处 《山东医药》 CAS 北大核心 2010年第43期94-95,共2页 Shandong Medical Journal
  • 相关文献

参考文献3

  • 1郝春芳,江泽飞,宋三泰.乳腺癌新辅助化疗若干问题的讨论[J].国外医学(肿瘤学分册),2003,30(2):116-118. 被引量:20
  • 2张之南主编..血液病诊断及疗效标准 第2版[M].北京:科学出版社,1998:434.
  • 3周际昌主编..实用肿瘤内科学[M].北京:人民卫生出版社,1999:639.

二级参考文献18

  • 1Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18 [J]. Cancer, 2002,95(4):681-695. 被引量:1
  • 2van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902[J]. J Clin Oncol, 2001,19(22): 4224-4237. 被引量:1
  • 3Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility [ J ]. Ann Surg Oncol,2002,9(3) : 228-234. 被引量:1
  • 4Ezzat AA, Ibrahim EM, Ajarim DS, et al . High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin [J]. Breast Cancer Res Treat, 2000,62(3):237-244. 被引量:1
  • 5Buzdar AU, Singletary SE, Valero V, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer:preliminary data of a prospective randomized trial [ J ]. Clin Cancer Res, 2002,8(5): 1073-1079. 被引量:1
  • 6Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel[J]. J Clin Oncol, 2002,20(6): 1456-1466. 被引量:1
  • 7NSABP. The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results from NSABP Protocol B-27 [ J ].Breast Cancer Res Treat,2001,69:210a. 被引量:1
  • 8Wenzel C, Locker GJ, Pluschnig U, et al. Phase Ⅰ/Ⅱ trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer [J]. Cancer Chemother Pharmacol, 2002,50(2): 155-159. 被引量:1
  • 9Gregory RK, Powles TJ, Salter J, et al. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy [J]. Breast Cancer Res Treat, 2000, 59(2): 171-175. 被引量:1
  • 10Estevez LG, Cuevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage Ⅱ and Ⅲ breast cancer: efficacy and correlative with biological markers in a phase Ⅱ, multicenter study [J]. Clin Cancer Res, 2003,9(2): 686-692. 被引量:1

共引文献19

同被引文献130

引证文献12

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部